CN102389392A - Recombinant bovine basic fibroblast growth factor gel for eye use - Google Patents
Recombinant bovine basic fibroblast growth factor gel for eye use Download PDFInfo
- Publication number
- CN102389392A CN102389392A CN2011103424365A CN201110342436A CN102389392A CN 102389392 A CN102389392 A CN 102389392A CN 2011103424365 A CN2011103424365 A CN 2011103424365A CN 201110342436 A CN201110342436 A CN 201110342436A CN 102389392 A CN102389392 A CN 102389392A
- Authority
- CN
- China
- Prior art keywords
- gel
- fibroblast growth
- growth factor
- basic fibroblast
- bovine basic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101001051969 Bos taurus Fibroblast growth factor 2 Proteins 0.000 title claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000008215 water for injection Substances 0.000 claims abstract description 17
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 239000003223 protective agent Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 7
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 7
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 7
- 229920002125 Sokalan® Polymers 0.000 claims description 7
- 229960001631 carbomer Drugs 0.000 claims description 7
- -1 hydroxypropyl Chemical group 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 238000005374 membrane filtration Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 230000008961 swelling Effects 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 4
- 241000283690 Bos taurus Species 0.000 abstract 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 abstract 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 230000005923 long-lasting effect Effects 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 210000001508 eye Anatomy 0.000 description 30
- 238000012360 testing method Methods 0.000 description 14
- 230000035876 healing Effects 0.000 description 12
- 210000003560 epithelium corneal Anatomy 0.000 description 8
- 239000013642 negative control Substances 0.000 description 7
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 6
- 210000004087 cornea Anatomy 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000009043 Chemical Burns Diseases 0.000 description 2
- 208000018380 Chemical injury Diseases 0.000 description 2
- 206010010984 Corneal abrasion Diseases 0.000 description 2
- 208000028006 Corneal injury Diseases 0.000 description 2
- 208000020564 Eye injury Diseases 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 206010037508 Punctate keratitis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010064996 Ulcerative keratitis Diseases 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 201000007717 corneal ulcer Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 206010023365 keratopathy Diseases 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 208000005494 xerophthalmia Diseases 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003683 corneal stroma Anatomy 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000002691 topical anesthesia Methods 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a recombinant bovine basic fibroblast growth factor gel for eye use and a preparation method thereof. The gel for eye use contains the following ingredients with the dosage: 1000 to 3000 IU of recombinant bovine basic fibroblast growth factors, 0.01 to 0.25 mg of a protein protectant, 0.5 to 1.5 mg of a gel matrix, an appropriate amount of a pH regulator, and water for injection added to 0.4 g. The product has the characteristics of having less irritation, being easy to apply and having a long-lasting action.
Description
Technical field
The present invention relates to field of biological product.Particularly relate to a kind of bFGF bovine basic fibroblast growth factor gel for eye use and preparation method thereof.
Background technology
Basic fibroblast growth factor (Basic fibroblast growth factor; Be abbreviated as bFGF) mainly be distributed in the histoorgan in mesoderm and neural germinal layer source, many histiocytes there is effect, can promote cell division; Regulate cellular metabolism; Influence form, infiltration, differentiation and the aging of cell, the epithelial cell stromal cell of corneal nuclear endotheliocyte all can exert an influence, and the reparation of regeneration, corneal stroma and the endodermis of alkali burn corneal epithelium is all had facilitation.
BFGF bovine basic fibroblast growth factor (Recombinant bovine basic fibroblast growth factor; Be abbreviated as rb-bFGF) be the escherichia coli that efficiently express the human/bovine basic fibroblast growth factor gene by containing, through fermentation, separation and highly purified after the active factors that obtains.Rb-bFGF can treat corneal epithelial defect and point-like keratopathy, recurrent superficial punctate keratopathy, light moderate xerophthalmia, bullous keratitis, corneal abrasion, light moderate chemical burn, the operation on cornea that a variety of causes causes and the postoperative healing is bad, the single phlyctenular corneal ulcer of map shape (or trophism) etc.
Gel for eye use is a kind of gel that is used for eye and since the preparation that is used for eye require fine and smooth even, non-stimulated, be prone to coating etc., therefore, gel for eye use is extremely tight with the consumption requirement to the kind of adjuvant.Simultaneously, in order to obtain persistent drug effect, the selection of gel-type vehicle is also extremely important in the gel for eye use.
One Chinese patent application 200510036465 (the application people is Nanhai Longtime Pharmaceutical Co., Ltd.) discloses a kind of recombination human basic fibroblast growth factor exterior-applied gel that is used to treat diseases such as burn wound; It is made up of recombination human basic fibroblast growth factor stock solution and pharmaceutically acceptable auxiliaries, and wherein pharmaceutically acceptable auxiliaries is selected from Acritamer 940 NF, hyaluronate sodium, trehalose, mannitol, Dextran 40, heparin sodium.One Chinese patent application 200510009218 (the application people is the upright Pharmaceutical Technology Co., Ltd of the two aigrets in Beijing) discloses a kind of recombination human basic fibroblast growth factor exterior-applied gel of treating diseases such as wound, burn and scald, and its gel-type vehicle comprises thickening agent (being selected from sodium carboxymethyl cellulose, methylcellulose, Polyethylene Glycol, carbomer, chitosan that percentage by weight is 0.1-10%), wetting agent, antiseptic, stabilizing agent, pH regulator agent and water.
Though disclosing the gel and the adjuvant thereof of recombination human basic fibroblast growth factor, above-mentioned two patent applications form; But they only are fit to treat wound etc. through the approach of topical administration, and do not do any instruction for how bFGF bovine basic fibroblast growth factor being selected to prepare the gel that is applicable to eye through specific adjuvant.
Therefore, the recombination human basic fibroblast growth factor gel for eye use that needs little, the easy coating of a kind of zest of exploitation, lasting medicine is still arranged.
Summary of the invention
The purpose of this invention is to provide bFGF bovine basic fibroblast growth factor gel for eye use of little, the easy coating of a kind of zest, lasting medicine and preparation method thereof.
Goal of the invention of the present invention realizes through following embodiment.
A kind of bFGF bovine basic fibroblast growth factor gel for eye use is characterized in that the component of said gel for eye use and consumption are:
BFGF bovine basic fibroblast growth factor 1000-3000IU;
Protein protective agent 0.01-0.25mg;
Gel-type vehicle 0.5-1.5mg;
The pH regulator agent is an amount of;
Water for injection adds to 0.4ml;
Wherein, described protein protective agent is selected from human albumin, mannitol and Polyethylene Glycol, preferred human albumin; Described gel-type vehicle is selected from hydroxypropyl emthylcellulose and carbomer; Described pH regulator agent is sodium hydroxide or hydrochloric acid;
One preferred embodiment in, the component of bFGF bovine basic fibroblast growth factor gel for eye use and consumption are:
BFGF bovine basic fibroblast growth factor 1680IU;
Protein protective agent 0.2mg;
Gel-type vehicle 1.00mg;
The pH regulator agent is an amount of;
Water for injection adds to 0.4ml;
Wherein, described protein protective agent is the human albumin; Described gel-type vehicle is hydroxypropyl emthylcellulose and carbomer; Described pH regulator agent is sodium hydroxide or hydrochloric acid;
The method for preparing of bFGF bovine basic fibroblast growth factor gel for eye use of the present invention comprises following steps:
(1) with gel-type vehicle with an amount of water for injection swelling, adjust pH makes the formation clear gel, then at 121 ℃ of pressure sterilizings, cooling back is subsequent use;
(2) bFGF bovine basic fibroblast growth factor and protein protective agent are dissolved in the proper amount of water for injection, with 0.22 μ m membrane filtration degerming;
(3) the solution mix homogeneously that clear gel that under aseptic condition, step (1) is obtained and step (2) obtain, packing promptly gets.
Preferably, method for preparing is:
(1) with the 0.5-1.5mg gel-type vehicle with an amount of water for injection swelling, adjust pH makes the formation clear gel, then at 121 ℃ of pressure sterilizings, cooling back is subsequent use;
(2) 1000-3000IU bFGF bovine basic fibroblast growth factor and 0.01-0.25mg protein protective agent are dissolved in the proper amount of water for injection, with 0.22 μ m membrane filtration degerming;
(3) the solution mix homogeneously that clear gel that under aseptic condition, step (1) is obtained and step (2) obtain, packing promptly gets.
The present invention has following advantage and effect:
1. gel for eye of the present invention is to suffer from corneal epithelial defect and point-like keratopathy, recurrent superficial punctate keratopathy, light moderate xerophthalmia, bullous keratitis, corneal abrasion, light moderate chemical burn, the operation on cornea that a variety of causes causes and the postoperative healing is bad, the ocular disease patient of the single phlyctenular corneal ulcer of map shape (or trophism) etc. provides a kind of interchangeable administration form;
2. gel for eye of the present invention be prone to coating, fine and smooth evenly, persistent, to the eye nonirritant;
3. gel for eye of the present invention is easy to use, economical and practical, has increased patient's compliance.
The specific embodiment
Do further explanation below in conjunction with preferred embodiment of the present invention, these embodiment are interpreted as can not limiting practical range of the present invention, and its modification and equivalent way all covered in protection scope of the present invention.
Embodiment 1:
Prescription:
Concrete method for preparing is:
With hydroxypropyl emthylcellulose with an amount of water for injection swelling, adjust pH makes the formation clear gel, and then at 121 ℃ of pressure sterilizings, the cooling back is subsequent use; BFGF bovine basic fibroblast growth factor and human albumin are dissolved in the proper amount of water for injection, with 0.22 μ m membrane filtration degerming; With above-mentioned clear gel and filtrating mix homogeneously, packing promptly gets under aseptic condition.
Embodiment 2:
Prescription:
Concrete method for preparing is:
With carbomer, hydroxypropyl emthylcellulose with an amount of water for injection swelling, adjust pH makes the formation clear gel, and then at 121 ℃ of pressure sterilizings, the cooling back is subsequent use; BFGF bovine basic fibroblast growth factor, human albumin and mannitol risen be dissolved in the proper amount of water for injection, with 0.22 μ m membrane filtration degerming; With above-mentioned clear gel and filtrating mix homogeneously, packing promptly gets under aseptic condition.
Embodiment 3:
Prescription:
Concrete method for preparing is:
With carbomer with an amount of water for injection swelling, adjust pH makes the formation clear gel, and then at 121 ℃ of pressure sterilizings, the cooling back is subsequent use; BFGF bovine basic fibroblast growth factor, mannitol and Polyethylene Glycol are dissolved in the proper amount of water for injection, with 0.22 μ m membrane filtration degerming; With above-mentioned clear gel and filtrating mix homogeneously, packing promptly gets under aseptic condition.
Test Example 1:rb-bFGF gel for eye use promotes the experimentation of corneal alkali burn model healing
1, test method
Experimental animal: healthy new zealand white rabbit, body weight 2-3kg, male and female and usefulness, pocket lamp and slit lamp examination anterior chamber of eye no abnormality seen.120 animals are divided into five groups at random, every group of 24 animals.
The rabbit cornea model of alkali burned: the examination of external eye intact animal, normal saline drips washes right eye 2 times, with 0.5% tetracaine eye drop eye drip 2 times; Topical anesthesia, intramuscular injection ketamine (50mg/kg), general anesthesia; Filter paper dick is soaked in 0.5mol/L NaOH solution, remove unnecessary liquid, carefully sticked in the cornea of right eye center district of fixing eyeball position several minutes; Use normal saline flushing cornea and conjunctival sac immediately after taking off filter paper, promptly process the corneal alkali burn model.
Test specimen: the negative control article are not for containing the gel for eye use of bFGF bovine basic fibroblast growth factor, and adjuvant is formed with embodiment 1, are applied to eye injury place every day sooner or later respectively once; Sample of the present invention is embodiment 1 gel for eye use, is applied to eye injury place every day sooner or later respectively once; Positive reference substance is a Solcoseryl Eye-Jel, each one, and four times a day.
Medication: negative control article, gel for eye use of the present invention and positive reference substance respectively to the animal pattern administration, were treated for two weeks continuously.
Evaluation index: respectively treatment 1,2,4,6,10,14 day the time with fluorescent staining slit lamp microscope standard photograph photo, analyze through the computer picture systematic survey and respectively to organize different time corneal epithelium healing area (result sees table 1) and corneal epithelium healing rate (result sees table 2).Corneal epithelium healing area and corneal epithelium healing rate are high more, show that therapeutic effect is good more.
2, result of the test
Table 1, respectively organize the corneal epithelium healing area (mm of different time
2X ± S)
| Treatment time (my god) | Negative control group | Of the present invention group | Positive controls |
| 1 | 12.1±1.5 | 46.1±2.1 | 21.2±4.3 |
| 2 | 39.5±4.1 | 50.2±2.8 | 44.2±2.4 |
| 4 | 31.3±3.9 | 40.7±2.4 | 31.1±4.5 |
| 6 | 32.3±7.2 | 48.5±3.3 | 39.4±2.5 |
| 10 | 37.2±2.4 | 50.7±2.4 | 46.2±4.3 |
| 14 | 35.2±6.5 | 51.2±3.4 | 44.9±4.5 |
Table 2. is respectively organized the corneal epithelium healing rate (% of different time; X ± S)
| Treatment time (my god) | Negative control group | Of the present invention group | Positive controls |
| 1 | 28.3±1.5 | 95.0±1.6 | 41.8±7.3 |
| 2 | 77.1±2.2 | 99.8±0.7 | 87.2±2.5 |
| 4 | 61.1±6.7 | 80.9±6.2 | 61.3±7.4 |
| 6 | 63.1±7.3 | 96.4±1.9 | 77.7±4.3 |
| 10 | 72.7±4.2 | 100±1.1 | 91.1±6.3 |
| 14 | 68.7±8.3 | 100±0.8 | 88.6±3.8 |
Result by table 1 and table 2 can find out that in the time of the 1st day, of the present invention group epithelium healing area is obviously greater than negative control group and positive controls; In the time of the 4th day, the epithelium healing rate appears necessarily repeatedly; When the 10th day and the 14th day, of the present invention group corneal epithelium healing rate is greater than negative control group and positive controls, and with negative control group significant difference arranged.
Test Example 2: stability study
1, high temperature and humidity test:
The gel for eye use fill of embodiment 1 is sealed in the aluminum pipe in undercoating; Sealing places under 60 ℃, relative humidity 75% condition carries out accelerated tests, respectively at the content, pH, outward appearance, stretchability, the aseptic and centrifugal test (300r/min) that detected gel in 1,5,10 day.Result such as following table:
Table 3, hot and humid result
| 1 day | 5 days | 10 days | |
| Content | 99.99％ | 99.98％ | 99.95％ |
| pH | 7.0 | 7.0 | 7.0 |
| Outward appearance | Water white transparency | Water white transparency | Water white transparency |
| Stretchability | Good | Good | Good |
| Aseptic | Qualified | Qualified | Qualified |
| Centrifugal test | No layering | No layering | No layering |
The result shows, gel for eye use of the present invention steady quality in high temperature and humidity test.
2, low-temperature test:
The gel for eye use fill of embodiment 1 is sealed in the aluminum pipe in undercoating, and sealing places under 4 ℃ and experimentizes, respectively at 1,3, detect content, pH, outward appearance, stretchability, the aseptic and centrifugal test (300r/min) of gel June.Result such as following table:
Table 4, low-temperature test result
| 1 month | 3 months | 6 months | |
| Content | 100.01％ | 99.98％ | 99.95％ |
| pH | 7.0 | 7.0 | 7.0 |
| Outward appearance | Water white transparency | Water white transparency | Water white transparency |
| Stretchability | Good | Good | Good |
| Aseptic | Qualified | Qualified | Qualified |
| Centrifugal test | No layering | No layering | No layering |
The result shows, gel for eye use of the present invention steady quality in low-temperature test.
Claims (3)
1. bFGF bovine basic fibroblast growth factor gel for eye use is characterized in that the component of said gel for eye use and consumption are:
BFGF bovine basic fibroblast growth factor 1000-3000IU;
Protein protective agent 0.01-0.25mg;
Gel-type vehicle 0.5-1.5mg;
The pH regulator agent is an amount of;
Water for injection adds to 0.4ml;
Wherein, described protein protective agent is selected from human albumin, mannitol and Polyethylene Glycol, and described gel-type vehicle is selected from hydroxypropyl emthylcellulose and carbomer, and described pH regulator agent is sodium hydroxide or hydrochloric acid;
2. bFGF bovine basic fibroblast growth factor gel for eye use according to claim 1 is characterized in that the component of said gel for eye use and consumption are:
BFGF bovine basic fibroblast growth factor 1680IU;
Protein protective agent 0.2mg;
Gel-type vehicle 1.00mg;
The pH regulator agent is an amount of;
Water for injection adds to 0.4ml;
Wherein, described protein protective agent is the human albumin; Described gel-type vehicle is hydroxypropyl emthylcellulose and carbomer; Described pH regulator agent is sodium hydroxide or hydrochloric acid;
3. the method for preparing of bFGF bovine basic fibroblast growth factor gel for eye use according to claim 1 is characterized in that comprising following steps:
(1) with gel-type vehicle with an amount of water for injection swelling, adjust pH makes the formation clear gel, then at 121 ℃ of pressure sterilizings, cooling back is subsequent use;
(2) bFGF bovine basic fibroblast growth factor and protein protective agent are dissolved in the proper amount of water for injection, with 0.22 μ m membrane filtration degerming;
(3) the solution mix homogeneously that clear gel that under aseptic condition, step (1) is obtained and step (2) obtain, packing promptly gets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110342436A CN102389392B (en) | 2011-11-02 | 2011-11-02 | Recombinant bovine basic fibroblast growth factor gel for eye use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110342436A CN102389392B (en) | 2011-11-02 | 2011-11-02 | Recombinant bovine basic fibroblast growth factor gel for eye use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102389392A true CN102389392A (en) | 2012-03-28 |
| CN102389392B CN102389392B (en) | 2012-10-24 |
Family
ID=45856860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110342436A Expired - Fee Related CN102389392B (en) | 2011-11-02 | 2011-11-02 | Recombinant bovine basic fibroblast growth factor gel for eye use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102389392B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104546692A (en) * | 2015-02-12 | 2015-04-29 | 珠海亿胜生物制药有限公司 | Recombinant calf alkaline fibroblast growth factor ophthalmic gel |
| CN104606667A (en) * | 2015-02-12 | 2015-05-13 | 珠海亿胜生物制药有限公司 | Recombinant bovine basic fibroblast growth factor gel |
| CN104984326A (en) * | 2015-07-14 | 2015-10-21 | 珠海亿胜生物制药有限公司 | Recombinant human basic fibroblast growth factor gel without bacteriostatic agent and preparation method thereof |
| JP2020533015A (en) * | 2017-06-23 | 2020-11-19 | 珠海億勝生物製薬有限公司 | A pharmaceutical composition containing recombinant human basic fibroblast growth factor (rh-bFGF) and rh-bFGF. |
| CN113069533A (en) * | 2021-03-08 | 2021-07-06 | 温州医科大学 | Long-acting fibroblast growth factor gel |
| CN115607506A (en) * | 2022-12-17 | 2023-01-17 | 朗肽生物制药股份有限公司 | Preparation method of anhydrous ointment containing recombinant human basic fibroblast growth factor |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0267015A2 (en) * | 1986-11-05 | 1988-05-11 | Ethicon, Inc. | Stabilized compositions containing epidermal growth factor |
| CN1733294A (en) * | 2005-08-10 | 2006-02-15 | 南海朗肽制药有限公司 | Recombined human alkaline fibroblast growth factor gelling agent and process for preparing the same |
| CN1814279A (en) * | 2005-01-31 | 2006-08-09 | 北京双鹭立生医药科技有限公司 | Regenerated human alkali fiber-cell growth factor gel former and preparing method |
-
2011
- 2011-11-02 CN CN201110342436A patent/CN102389392B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0267015A2 (en) * | 1986-11-05 | 1988-05-11 | Ethicon, Inc. | Stabilized compositions containing epidermal growth factor |
| CN1814279A (en) * | 2005-01-31 | 2006-08-09 | 北京双鹭立生医药科技有限公司 | Regenerated human alkali fiber-cell growth factor gel former and preparing method |
| CN1733294A (en) * | 2005-08-10 | 2006-02-15 | 南海朗肽制药有限公司 | Recombined human alkaline fibroblast growth factor gelling agent and process for preparing the same |
Non-Patent Citations (3)
| Title |
|---|
| OJU JEON ET AL: "Control of basic fibroblast growth factor release from fibrin gel with heparin and concentrations of fibrinogen and thrombin", 《JOURNAL OF CONTROLLED RELEASE》, vol. 105, 24 May 2005 (2005-05-24), pages 249 - 259, XP004969769, DOI: doi:10.1016/j.jconrel.2005.03.023 * |
| 杨丽萍 等: "重组牛碱性成纤维细胞生长因子眼凝胶在眼部皮肤外伤的应用与护理", 《医学研究生学报》, vol. 24, no. 7, 31 July 2011 (2011-07-31), pages 736 * |
| 杨洪存 等: "重组碱性成纤维细胞生长因子凝胶剂的制备", 《中国生物制品学杂志》, vol. 22, no. 10, 31 October 2009 (2009-10-31), pages 1002 - 1004 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104546692A (en) * | 2015-02-12 | 2015-04-29 | 珠海亿胜生物制药有限公司 | Recombinant calf alkaline fibroblast growth factor ophthalmic gel |
| CN104606667A (en) * | 2015-02-12 | 2015-05-13 | 珠海亿胜生物制药有限公司 | Recombinant bovine basic fibroblast growth factor gel |
| CN104606667B (en) * | 2015-02-12 | 2016-04-13 | 珠海亿胜生物制药有限公司 | BFGF bovine basic fibroblast growth factor gel |
| CN104984326A (en) * | 2015-07-14 | 2015-10-21 | 珠海亿胜生物制药有限公司 | Recombinant human basic fibroblast growth factor gel without bacteriostatic agent and preparation method thereof |
| JP2020533015A (en) * | 2017-06-23 | 2020-11-19 | 珠海億勝生物製薬有限公司 | A pharmaceutical composition containing recombinant human basic fibroblast growth factor (rh-bFGF) and rh-bFGF. |
| US11254723B2 (en) | 2017-06-23 | 2022-02-22 | Zhuhai Essex Bio-Pharmaceutical Co., Ltd. | Recombinant human-basic fibroblast growth factor (rh-bFGF) and pharmaceutical composition comprising rh-bFGF |
| JP7044870B2 (en) | 2017-06-23 | 2022-03-30 | 珠海億勝生物製薬有限公司 | A pharmaceutical composition containing recombinant human basic fibroblast growth factor (rh-bFGF) and rh-bFGF. |
| CN113069533A (en) * | 2021-03-08 | 2021-07-06 | 温州医科大学 | Long-acting fibroblast growth factor gel |
| CN115607506A (en) * | 2022-12-17 | 2023-01-17 | 朗肽生物制药股份有限公司 | Preparation method of anhydrous ointment containing recombinant human basic fibroblast growth factor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102389392B (en) | 2012-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102389392B (en) | Recombinant bovine basic fibroblast growth factor gel for eye use | |
| FI79554B (en) | FOERFARANDE FOER FRAMSTAELLNING AV HYALURONSYRAFRAKTIONER MED FARMACEUTISK AKTIVITET. | |
| CN101972470B (en) | An ophthalmic in situ gel | |
| Karthikeyan et al. | The concept of ocular inserts as drug delivery systems: An overview | |
| CN103212075A (en) | Eye drop containing VEGF antagonist | |
| CN101947309A (en) | Human basic fibroblast growth factor eye drops and preparation method thereof | |
| CN114425033B (en) | Eye gel containing mesenchymal stem cell exosomes and preparation method thereof | |
| Wang et al. | Lollipop‐inspired multilayered drug delivery hydrogel for dual effective, long‐term, and NIR‐defined glaucoma treatment | |
| CN102357242B (en) | Recombination cattle alkaline fibroblast growth factor gel | |
| CN102357243B (en) | Recombinant cattle basic fibroblastic growth factor eye drops | |
| Acosta et al. | Treatment of corneal ulcers with platelet rich plasma | |
| CN108379558A (en) | Application of the interleukin 22 in the drug for preparing treatment persistent corneal epithelial defects | |
| CN105012235B (en) | A kind of ophthalmically acceptable antimycotic nano micellar solution containing terbinafine HCl | |
| CN104606666B (en) | BFGF bovine basic fibroblast growth factor eye drop | |
| KR101840256B1 (en) | A water-soluble eye drop composition for the treatment of dry eye syndrome containing rebamipide and its solubilization and stabilization method | |
| CN101648019A (en) | Medicinal composition for treating ophthalmic inflammation and application thereof | |
| US11077193B2 (en) | Nerve growth factor composition and powder injection | |
| CN109593117B (en) | Polypeptide CKA18N for inhibiting angiogenesis and application thereof | |
| CN114980839A (en) | Stable formulations of silk proteins | |
| CN102188695A (en) | Ophthalmic gel composition | |
| CN102008488A (en) | Triamcinolone acetonide ophthalmic preparation and preparation method thereof | |
| CN110859835B (en) | Application of Butylphthalide in the Preparation of Medicines for Treating Corneal Injury | |
| CN104546692B (en) | BFGF bovine basic fibroblast growth factor gel for eye use | |
| CN101537172B (en) | An eye drop containing recombinant human keratinocyte growth factor-2 and its preparation method | |
| CN111330081B (en) | Preparation method of medicine-carrying amniotic membrane and influence of medicine-carrying amniotic membrane on corneal epithelium repair |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121024 Termination date: 20131102 |